Teva announces Phase III results for allergy spray; Ipsen gets FDA go-ahead for drug delivery syringe;

> Ipsen Biopharmaceuticals received FDA approval for its low-volume, full-dose, one-time-use syringe made to deliver Somatuline Depot (lanreotide). Release

> Teva ($TEVA) announced positive findings in its phase III clinical study on children suffering from year-round and seasonal allergic rhinitis using QNASL, its waterless aerosol intranasal corticosteroid spray. Release

> Maine-based DoseOne, maker of the DoseOne single-dose dry powder inhaler, is looking for a device or pharmaceutical partner to bring the drug delivery device to market. Release